DPCPX   Click here for help

GtoPdb Ligand ID: 386

Synonyms: 1,3-DPCPX | 8-cyclopentyl-1,3-dipropylxanthine | GNF-Pf-2224
Compound class: Synthetic organic
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species

DPCPX is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 3
Hydrogen bond donors 1
Rotatable bonds 5
Topological polar surface area 72.68
Molecular weight 304.19
XLogP 4.69
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES CCCn1c2nc([nH]c2c(=O)n(c1=O)CCC)C1CCCC1
Isomeric SMILES CCCn1c2nc([nH]c2c(=O)n(c1=O)CCC)C1CCCC1
InChI InChI=1S/C16H24N4O2/c1-3-9-19-14-12(15(21)20(10-4-2)16(19)22)17-13(18-14)11-7-5-6-8-11/h11H,3-10H2,1-2H3,(H,17,18)
InChI Key FFBDFADSZUINTG-UHFFFAOYSA-N
References
1. Auchampach JA, Jin X, Wan TC, Caughey GH, Linden J. (1997)
Canine mast cell adenosine receptors: cloning and expression of the A3 receptor and evidence that degranulation is mediated by the A2B receptor.
Mol Pharmacol, 52 (5): 846-60. [PMID:9351976]
2. Auchampach JA, Kreckler LM, Wan TC, Maas JE, van der Hoeven D, Gizewski E, Narayanan J, Maas GE. (2009)
Characterization of the A2B adenosine receptor from mouse, rabbit, and dog.
J Pharmacol Exp Ther, 329 (1): 2-13. [PMID:19141710]
3. de Ligt RA, Rivkees SA, Lorenzen A, Leurs R, IJzerman AP. (2005)
A "locked-on," constitutively active mutant of the adenosine A1 receptor.
Eur J Pharmacol, 510 (1-2): 1-8. [PMID:15740718]
4. Dionisotti S, Ongini E, Zocchi C, Kull B, Arslan G, Fredholm BB. (1997)
Characterization of human A2A adenosine receptors with the antagonist radioligand [3H]-SCH 58261.
Br J Pharmacol, 121 (3): 353-60. [PMID:9179373]
5. Fozard JR, Baur F, Wolber C. (2003)
Antagonist pharmacology of adenosine A2B receptors from rat, guinea pig and dog.
Eur J Pharmacol, 475 (1-3): 79-84. [PMID:12954362]
6. Hayallah AM, Sandoval-Ramírez J, Reith U, Schobert U, Preiss B, Schumacher B, Daly JW, Müller CE. (2002)
1,8-disubstituted xanthine derivatives: synthesis of potent A2B-selective adenosine receptor antagonists.
J Med Chem, 45 (7): 1500-10. [PMID:11906291]
7. Iredale PA, Alexander SP, Hill SJ. (1994)
Coupling of a transfected human brain A1 adenosine receptor in CHO-K1 cells to calcium mobilisation via a pertussis toxin-sensitive mechanism.
Br J Pharmacol, 111 (4): 1252-6. [PMID:8032613]
8. Kim SA, Marshall MA, Melman N, Kim HS, Müller CE, Linden J, Jacobson KA. (2002)
Structure-activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions.
J Med Chem, 45 (11): 2131-8. [PMID:12014951]
9. Klotz KN, Hessling J, Hegler J, Owman C, Kull B, Fredholm BB, Lohse MJ. (1998)
Comparative pharmacology of human adenosine receptor subtypes - characterization of stably transfected receptors in CHO cells.
Naunyn Schmiedebergs Arch Pharmacol, 357 (1): 1-9. [PMID:9459566]
10. Klotz KN, Vogt H, Tawfik-Schlieper H. (1991)
Comparison of A1 adenosine receptors in brain from different species by radioligand binding and photoaffinity labelling.
Naunyn Schmiedebergs Arch Pharmacol, 343 (2): 196-201. [PMID:2067592]
11. Kull B, Arslan G, Nilsson C, Owman C, Lorenzen A, Schwabe U, Fredholm BB. (1999)
Differences in the order of potency for agonists but not antagonists at human and rat adenosine A2A receptors.
Biochem Pharmacol, 57 (1): 65-75. [PMID:9920286]
12. Müller CE, Maurinsh J, Sauer R. (2000)
Binding of [3H]MSX-2 (3-(3-hydroxypropyl)-7-methyl-8-(m-methoxystyryl)-1-propargylxanthine) to rat striatal membranes--a new, selective antagonist radioligand for A(2A) adenosine receptors.
Eur J Pharm Sci, 10 (4): 259-65. [PMID:10838015]
13. Obiefuna PC, Batra VK, Nadeem A, Borron P, Wilson CN, Mustafa SJ. (2005)
A novel A1 adenosine receptor antagonist, L-97-1 [3-[2-(4-aminophenyl)-ethyl]-8-benzyl-7-{2-ethyl-(2-hydroxy-ethyl)-amino]-ethyl}-1-propyl-3,7-dihydro-purine-2,6-dione], reduces allergic responses to house dust mite in an allergic rabbit model of asthma.
J Pharmacol Exp Ther, 315 (1): 329-36. [PMID:16020631]
14. Olah ME, Jacobson KA, Stiles GL. (1994)
Role of the second extracellular loop of adenosine receptors in agonist and antagonist binding. Analysis of chimeric A1/A3 adenosine receptors.
J Biol Chem, 269 (40): 24692-8. [PMID:7929142]
15. Ongini E, Dionisotti S, Gessi S, Irenius E, Fredholm BB. (1999)
Comparison of CGS 15943, ZM 241385 and SCH 58261 as antagonists at human adenosine receptors.
Naunyn Schmiedebergs Arch Pharmacol, 359 (1): 7-10. [PMID:9933143]
16. Rivkees SA, Barbhaiya H, IJzerman AP. (1999)
Identification of the adenine binding site of the human A1 adenosine receptor.
J Biol Chem, 274 (6): 3617-21. [PMID:9920910]
17. Salvatore CA, Jacobson MA, Taylor HE, Linden J, Johnson RG. (1993)
Molecular cloning and characterization of the human A3 adenosine receptor.
Proc Natl Acad Sci USA, 90 (21): 10365-9. [PMID:8234299]
18. Stewart M, Steinig AG, Ma C, Song JP, McKibben B, Castelhano AL, MacLennan SJ. (2004)
[3H]OSIP339391, a selective, novel, and high affinity antagonist radioligand for adenosine A2B receptors.
Biochem Pharmacol, 68 (2): 305-12. [PMID:15194002]
19. Varani K, Merighi S, Gessi S, Klotz KN, Leung E, Baraldi PG, Cacciari B, Romagnoli R, Spalluto G, Borea PA. (2000)
[(3)H]MRE 3008F20: a novel antagonist radioligand for the pharmacological and biochemical characterization of human A(3) adenosine receptors.
Mol Pharmacol, 57 (5): 968-75. [PMID:10779381]
20. Weyler S, Fülle F, Diekmann M, Schumacher B, Hinz S, Klotz KN, Müller CE. (2006)
Improving potency, selectivity, and water solubility of adenosine A1 receptor antagonists: xanthines modified at position 3 and related pyrimido[1,2,3-cd]purinediones.
ChemMedChem, 1 (8): 891-902. [PMID:16902942]